Transition of oncology programme into lead optimisation triggers EUR 2.0M milestone payment to Evotec

Download PDF Copy

Editorial Checklist

Reviewed

Evotec AGJan 13 2011

NewsGuard 100/100 Score

Evotec AG (Frankfurt:EVT) today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.0 million to Evotec. The milestone reached was on the transition of an oncology programme into lead optimisation.

Dr Mario Polywka, Chief Operating Officer of Evotec commented: "This is the eleventh milestone achieved as part of this alliance with Boehringer Ingelheim and the second against an oncology target. We continue to enjoy a very rich scientific partnership with Boehringer Ingelheim and look forward to continued success through our joint project teams in the coming years."

Source:

Posted in: Medical Research News | Medical Condition News

Tags: Biotechnology, Cardiometabolic, Depression, Neuroscience, Oncology, Research

Comments (0)

Download PDF Copy

Suggested Reading

Cetuximab performs better than durvalumab in treating head and neck cancers

Cetuximab performs better than durvalumab in treating head and neck cancers

Detection Technology launches advanced X-ray detector portfolio at RSNA 2024

Detection Technology launches advanced X-ray detector portfolio at RSNA 2024

IASLC and LCRF announce first grant recipient for lung cancer research

IASLC and LCRF announce first grant recipient for lung cancer research

Golgi apparatus plays crucial role in enhancing T-cell function against cancer

Golgi apparatus plays crucial role in enhancing T-cell function against cancer

University of Oklahoma professor honored with prestigious Palade Prize for pancreatic cancer research

University of Oklahoma professor honored with prestigious Palade Prize for pancreatic cancer research

Rare genetic mutations in healthy women may be key to breast cancer origins

Rare genetic mutations in healthy women may be key to breast cancer origins

New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer

New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer

Temozolomide and radiation combination improves survival in low-grade glioma patients

Temozolomide and radiation combination improves survival in low-grade glioma patients

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

MRI-guided SBRT reduces side effects in prostate cancer treatment